Intensive management of dyslipidemia in very high-risk patients with PCSK9 inhibitors

Authors: Viera Doničová 1;  Martina Gáborová 2
Authors‘ workplace: Diabetologická a metabolická ambulancia, Human-Care s. r. o. 1;  Ústav lekárskej fyziológie UPJŠ v Košiciach 2
Published in: AtheroRev 2019; 4(1): 49-52


In the case report on a patient with intolerance of statin therapy and a very high cardiovascular risk, we describe a beneficial effect of the treatment with the lipid profile target values achieved by a monoclonal antibody, the PCSK9 inhibitor.


alirocumab – high cardiovascular risk – PCSK9 inhibitor

  1. Catapano AL, Graham I, Guy de Backer et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058. Dostupné z DOI: <>.
  2. Steinberg D, Witztum JL. Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA 2009; 106: 9546–9547. Dostupné z DOI: <>.
  3. Gearing ME. A potential new weapon aginst heart disease: PCSK9 inhibitors. Science in the News 2015. Harvard University. Dostupné z WWW: <>.
  4. Li C, Lin L, Zhang W et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015; 4(6): e001937. Dostupné z DOI: <>.
  5. Janský P, Roslová H, Vrablík M. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2017; 59(4): e389–e415. Dostupné z DOI: <>.
  6. Vrablík M. Novinky v kardiovaskulární prevenci: od guidelines k novým léčebným možnostem. Interní Med Praxi 2015; 17(5): 233–238.
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account